1
|
Chang R, Liu J, Ji F, Fu L, Xu K, Yang Y, Ma A. Hypoglycemic effect of recrystallized resistant starch on high-fat diet- and streptozotocin-induced type 2 diabetic mice via gut microbiota modulation. Int J Biol Macromol 2024; 261:129812. [PMID: 38302033 DOI: 10.1016/j.ijbiomac.2024.129812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Revised: 01/21/2024] [Accepted: 01/25/2024] [Indexed: 02/03/2024]
Abstract
The hypoglycemic effects of two recrystallized resistant starches, A-type (ARS) and B-type (BRS), were investigated in type 2 diabetic mice. Mice were treated with low-, medium-, or high-dose ARS, high-dose BRS, or high-dose ARS combined with BRS (ABRS). After 10 weeks of continuous intervention, the medium-dose ARS group showed a significant reduction in fasting blood glucose, area under the curve of glucose, triglyceride (P < 0.01), and low-density lipoprotein (P < 0.05) levels compared to the model group and an increase in high-density lipoprotein levels (P < 0.01). The peptide YY and glucagon-like peptide-1 levels in the high-dose ARS, BRS, and ABRS groups and the butyric acid yield in the medium-dose ARS and BRS groups were significantly increased (P < 0.01) compared to those in the model group. Medium- and high-dose ARS intervention efficiently increased the relative abundance of beneficial Bacteroidetes, Lactobacillus, Lachnospiraceae_NK4A136_group, and Faecalibaculum, and lowered the ratio of Firmicutes to Bacteroidetes. Overall, ARS exhibited greater advantages than BRS in lowering blood sugar levels.
Collapse
Affiliation(s)
- Ranran Chang
- Institute of Nutrition and Health, Qingdao University, Qingdao 266021, China; School of Public Health, Qingdao University, Qingdao 266021, China; National Engineering Research Center of Seafood, Dalian Polytechnic University, Dalian 116034, China.
| | - Jie Liu
- Institute of Nutrition and Health, Qingdao University, Qingdao 266021, China; School of Public Health, Qingdao University, Qingdao 266021, China
| | - Fangfei Ji
- Institute of Nutrition and Health, Qingdao University, Qingdao 266021, China; School of Public Health, Qingdao University, Qingdao 266021, China; Shanghai Municipal Minhang District Health Promotion Centre, Shanghai 201199, China
| | - Lili Fu
- Institute of Nutrition and Health, Qingdao University, Qingdao 266021, China; School of Public Health, Qingdao University, Qingdao 266021, China
| | - Kunjie Xu
- Institute of Nutrition and Health, Qingdao University, Qingdao 266021, China; School of Public Health, Qingdao University, Qingdao 266021, China
| | - Yuexin Yang
- Institute of Nutrition and Health, Qingdao University, Qingdao 266021, China; School of Public Health, Qingdao University, Qingdao 266021, China; National Institute of Nutrition for Health, Chinese Center for Disease Control and Prevention, Beijing 100051, China
| | - Aiguo Ma
- Institute of Nutrition and Health, Qingdao University, Qingdao 266021, China; School of Public Health, Qingdao University, Qingdao 266021, China
| |
Collapse
|
2
|
Chen XY, Wang TT, Shen Q, Ma H, Li ZH, Yu XN, Huang XF, Qing LS, Luo P. Preclinical Investigations on Anti-fibrotic Potential of Long-Term Oral Therapy of Sodium Astragalosidate in Animal Models of Cardiac and Renal Fibrosis. ACS Pharmacol Transl Sci 2024; 7:421-431. [PMID: 38357273 PMCID: PMC10863439 DOI: 10.1021/acsptsci.3c00264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2023] [Revised: 12/08/2023] [Accepted: 12/19/2023] [Indexed: 02/16/2024]
Abstract
In traditional Chinese medicine, Radix Astragali has played a vital role in treating progressive fibrotic diseases. One of its main active components, astragaloside IV, is a promising anti-fibrotic treatment despite its extremely low bioavailability. Our study aimed to optimize sodium astragalosidate (SA) by salt formation to improve solubility and oral absorption for anti-fibrotic therapy in vivo. Isoproterenol-induced myocardial fibrosis rat models and obese BKS-db mice presenting diabetic kidney fibrosis were used in this study. Daily oral administration of SA (20 mg/kg) for 14 days ameliorated cardiac fibrosis by reducing collagen accumulation and fibrosis-related inflammatory signals, including TNF-α, IL-1β, and IL-6. In db/db mice, SA (5,10, and 20 mg/kg per day for 8 weeks) dose-dependently alleviated lipid metabolism impairment and renal dysfunction when administered orally. Furthermore, Western blot and immunohistochemistry analyses demonstrated that SA treatment inhibited renal fibrosis by suppressing TGF-β1/Smads signaling. Taken together, our findings provide the oral-route medication availability of SA, which thus might offer a novel lead compound in preclinical trial-enabling studies for developing a long-term therapy to treat and prevent fibrosis.
Collapse
Affiliation(s)
- Xiao-Yi Chen
- State
Key Laboratories for Quality Research in Chinese Medicines, Faculty
of Pharmacy, Macau University of Science
and Technology, Macau 999078, China
- Institute
of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China
| | - Tian-Tian Wang
- State
Key Laboratories for Quality Research in Chinese Medicines, Faculty
of Pharmacy, Macau University of Science
and Technology, Macau 999078, China
- Chengdu
Institute of Biology, Chinese Academy of
Sciences, Chengdu 610041, China
| | - Qing Shen
- State
Key Laboratories for Quality Research in Chinese Medicines, Faculty
of Pharmacy, Macau University of Science
and Technology, Macau 999078, China
- Collaborative
Innovation Center of Seafood Deep Processing, Zhejiang Province Joint
Key Laboratory of Aquatic Products Processing, Institute of Seafood, Zhejiang Gongshang University, Hangzhou 310012, China
| | - Hao Ma
- State
Key Laboratories for Quality Research in Chinese Medicines, Faculty
of Pharmacy, Macau University of Science
and Technology, Macau 999078, China
| | - Zhan-Hua Li
- State
Key Laboratories for Quality Research in Chinese Medicines, Faculty
of Pharmacy, Macau University of Science
and Technology, Macau 999078, China
| | - Xi-Na Yu
- State
Key Laboratories for Quality Research in Chinese Medicines, Faculty
of Pharmacy, Macau University of Science
and Technology, Macau 999078, China
| | - Xiao-Feng Huang
- Chengdu
Institute of Biology, Chinese Academy of
Sciences, Chengdu 610041, China
| | - Lin-Sen Qing
- Chengdu
Institute of Biology, Chinese Academy of
Sciences, Chengdu 610041, China
| | - Pei Luo
- State
Key Laboratories for Quality Research in Chinese Medicines, Faculty
of Pharmacy, Macau University of Science
and Technology, Macau 999078, China
| |
Collapse
|
3
|
Wu L, Wang A, Kang K, Zhang X, Zhao X, Wang W. Low LDL-C/HDL-C Ratio is Associated with Poor Clinical Outcome After Intracerebral Hemorrhage: A Retrospective Analysis of Multicenter, Prospective Cohort Data in China. Neurocrit Care 2023:10.1007/s12028-023-01905-z. [PMID: 38148436 DOI: 10.1007/s12028-023-01905-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2023] [Accepted: 11/20/2023] [Indexed: 12/28/2023]
Abstract
BACKGROUND The association between low-density lipoprotein cholesterol (LDL-C)/high-density lipoprotein cholesterol (HDL-C) ratio and the clinical outcomes of acute intracranial hemorrhage (ICH) remains unclear. In this study, we attempt to investigate whether low LDL-C/HDL-C ratio is associated with poor clinical outcomes in patients with ICH. METHODS The database was collected from a multicenter, prospective, observational cohort study, conducted in 13 hospitals in Beijing from January 2014 to September 2016. A total of 1,964 patients with ICH were initially screened in our database. Next, we selected patients with admission serum lipid information for retrospective analysis. Patients were categorized into four groups based on LDL-C/HDL-C ratio quartiles. The main outcomes were 30-day and 90-day poor functional outcome, which is defined as modified Rankin Scale score of 3 to 6, and 90-day all-cause death. Logistic regression was used to assess the association between LDL-C/HDL-C ratio and 30-day or 90-day poor functional outcome. Kaplan-Meier survival analysis and Cox regression were used to assess the association between LDL-C/HDL-C ratio and 90-day all-cause death. Restricted cubic splines were used to explore the nonlinear association between LDL-C/HDL-C ratio and the outcome of patients with ICH. RESULTS A total of 491 patients with spontaneous ICH were finally enrolled in our study. The mean age was 57.6 years old, and 72.1% (357/491) were men. After adjustment for confounders, patients in the lowest LDL-C/HDL-C quartile (< 1.74) had a significantly higher risk of 30-day and 90-day poor functional outcome compared with those in the highest quartile (> 3.16; 30-day: adjusted odds ratio 3.61, 95% confidence interval 1.68-7.72; 90-day: adjusted odds ratio 2.82, 95% confidence interval 1.33-5.95). Restricted cubic splines depicted a nonlinear association between LDL-C/HDL-C ratio and 90-day poor functional outcomes, indicating LDL-C/HDL-C ratio of 3.1-3.5 was correlated with better 90-day functional outcome. However, no significant correlation was found between low LDL-C/HDL-C ratio and 90-day all-cause death. CONCLUSIONS Lower LDL-C/HDL-C ratio (< 1.74) is independently associated with an increased risk of poor functional outcome in patients with ICH. In the population of patients whom we studied, there is a nonlinear association between LDL-C/HDL-C ratio and 90-day poor functional outcome, and patients with an LDL-C/HDL-C ratio of 3.1 to 3.5 tend to have the lowest risk of 90-day poor functional outcome.
Collapse
Affiliation(s)
- Lei Wu
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 119 West Road, South 4th Ring, Fengtai District, Beijing, People's Republic of China
- China National Clinical Research Center for Neurological Diseases, Capital Medical University, Beijing, People's Republic of China
| | - Anxin Wang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 119 West Road, South 4th Ring, Fengtai District, Beijing, People's Republic of China
- China National Clinical Research Center for Neurological Diseases, Capital Medical University, Beijing, People's Republic of China
| | - Kaijiang Kang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 119 West Road, South 4th Ring, Fengtai District, Beijing, People's Republic of China
- China National Clinical Research Center for Neurological Diseases, Capital Medical University, Beijing, People's Republic of China
- Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Xiaoli Zhang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 119 West Road, South 4th Ring, Fengtai District, Beijing, People's Republic of China
- China National Clinical Research Center for Neurological Diseases, Capital Medical University, Beijing, People's Republic of China
| | - Xingquan Zhao
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 119 West Road, South 4th Ring, Fengtai District, Beijing, People's Republic of China
- China National Clinical Research Center for Neurological Diseases, Capital Medical University, Beijing, People's Republic of China
- Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, People's Republic of China
| | - Wenjuan Wang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 119 West Road, South 4th Ring, Fengtai District, Beijing, People's Republic of China.
- China National Clinical Research Center for Neurological Diseases, Capital Medical University, Beijing, People's Republic of China.
| |
Collapse
|
4
|
Texis T, Rivera-Mancía S, Colín-Ramírez E, Cartas-Rosado R, Koepsell D, Rubio-Carrasco K, Rodríguez-Dorantes M, Gonzalez-Covarrubias V. Genetic Determinants of Atherogenic Indexes. Genes (Basel) 2023; 14:1214. [PMID: 37372394 DOI: 10.3390/genes14061214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Revised: 05/24/2023] [Accepted: 05/25/2023] [Indexed: 06/29/2023] Open
Abstract
Atherogenesis and dyslipidemia increase the risk of cardiovascular disease, which is the leading cause of death in developed countries. While blood lipid levels have been studied as disease predictors, their accuracy in predicting cardiovascular risk is limited due to their high interindividual and interpopulation variability. The lipid ratios, atherogenic index of plasma (AIP = log TG/HDL-C) and the Castelli risk index 2 (CI2 = LDL-C/HDL-C), have been proposed as better predictors of cardiovascular risk, but the genetic variability associated with these ratios has not been investigated. This study aimed to identify genetic associations with these indexes. The study population (n = 426) included males (40%) and females (60%) aged 18-52 years (mean 39 years); the Infinium GSA array was used for genotyping. Regression models were developed using R and PLINK. AIP was associated with variation on APOC3, KCND3, CYBA, CCDC141/TTN, and ARRB1 (p-value < 2.1 × 10-6). The three former were previously associated with blood lipids, while CI2 was associated with variants on DIPK2B, LIPC, and 10q21.3 rs11251177 (p-value 1.1 × 10-7). The latter was previously linked to coronary atherosclerosis and hypertension. KCND3 rs6703437 was associated with both indexes. This study is the first to characterize the potential link between genetic variation and atherogenic indexes, AIP, and CI2, highlighting the relationship between genetic variation and dyslipidemia predictors. These results also contribute to consolidating the genetics of blood lipid and lipid indexes.
Collapse
Affiliation(s)
- Tomas Texis
- National Institute of Genomic Medicine (INMEGEN), Mexico City 14610, Mexico
| | | | - Eloisa Colín-Ramírez
- School of Sports Sciences, Anahuac University of North Mexico, Huixquilucan 52786, Mexico
| | - Raul Cartas-Rosado
- National Institute of Cardiology Ignacio Chavez, Mexico City 14080, Mexico
| | - David Koepsell
- Conduct Research Committee, Texas A&M University, College Station, TX 77843, USA
| | - Kenneth Rubio-Carrasco
- National Institute of Genomic Medicine (INMEGEN), Mexico City 14610, Mexico
- School of Sports Sciences, Anahuac University of North Mexico, Huixquilucan 52786, Mexico
- Faculty of Chemistry UNAM, Mexico City 04510, Mexico
| | | | | |
Collapse
|